Possible correlation between immune and inflammatory profile and rheumatologic immune-related adverse events in oncologic patients treated with anti-PD-1/anti-PD-L1 checkpoints inhibitors.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma